[Irinotecan and tomudex in the treatment of patients with advanced cancer of the large intestine].
The data on the treatment of 82 patients with advanced colorektal carcinoma are presented. Tomudex was given as first-line treatment to 18 cases. Apparent response was reported in 31% including complete (6%) and partial (25%) regression. Tumor growth control (apparent response + stabilization) was registered in 62%. Median survival rate was 38.4 weeks. Neutropenia, diarrhea and hepatotoxicity formation limited the modality. The treatment can be recommended for out-patients thanks to good tolerability and practical convenience. The following regimens of irinotecan were employed as first- and second-line chemotherapy (64): 250-350 mg/sq.m, every three weeks (44) and 100-125 mg/sq.m/week, x 4 every 6 weeks (20). Response was 15 and 16%, tumor growth control--60 and 63%, median survival--41.6 and 51.6% weeks, respectively. Leuko- and neutropenia and diarrhea development limited both regimens. Weekly infusions seemed to offer more advantage for out-patient treatment, particularly, in feeble patients and those who are a high risk for grave side-effects. Tomudex and irinotecan toxicity was predictable, moderate, reversible and non-cumulative.
Reutova
E V
EV
N.N. Blokhin Center for Oncology Research, Russian Academy of Medical Sciences, Moscow.
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000401:mortality; D013876:Thiophenes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D011799:Quinazolines; D013876:Thiophenes; D000077146:Irinotecan; C068874:raltitrexed; D002166:Camptothecin